EPHX2 and fibrosarcoma: EPHX2 inhibitors can promote the progression of melanoma and fibrosarcoma in mouse models by increasing the level of endogenous lipid mediators, which indicates that there is a relationship between EPHX2-lipid metabolisms [50].